Pentraxin Therapeutics Limited

Glaxo Group Limited

Imperial College Innovations Limited

Pentraxin Therpeutics Limited

Mark Brian Pepys

Alan Peter Lewis

Volker Germaschewski

Susannah Karen Ford

Tejinder Kaur Bhinder

Steven Victor Ley

Simon Kolstoe

Martin Smith

Philip Nigel Hawkins

Thomas L Blundell

Angus John Morrison

Vittorio Bellotti

The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

Antigen binding proteins

The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.

Combinations of SAP depleting agents and anti-SAP antibodies

The present invention relates to compounds of formula (I) for stabilizing the tetrameric form of transthyretin, compounds for use in the treatment or prevention of amyloidosis, and agents and medicaments comprising such compounds. wherein X, Y, R, R, R, R, m, n, p, q, and the linker are as defined herein.

Compound and use thereof in the treatment of amyloidosis

Provided are agents and methods for use in depleting serum amyloid P component (SAP) from a patient in need thereof.

Therapeutic agent

A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.

Treatment and prevention of tissue damage

Agent for the depletion of an unwanted protein population from the plasma of a subject, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of the proteins in the presence thereof, wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins, wherein the agent is a non-proteinaceous agent other than a D-proline of the formula wherein the group

Use of an agent capable of inhibiting SAP ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.

Compounds inhibiting the binding of sap for treating osteoarthritis

An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the CRP molecules; or (ii) at least one of the ligands is capable of being bound by a ligand binding site present on a CRP molecule, and at least one other of the ligands is capable of being bound by a ligand binding site present on a serum amyloid P component (SAP) molecule.

The invention relates to an agent for the depletion of unwanted proteins from plasma comprising a plurality of ligands covalently co-linked to produce a complex with a plurality of proteins whierein at least two of the ligands are capable of being bound by ligand binding sites on the proteins and wherein the non-protein access agent excludes certain D-proline derivatives.

Growing community of inventors

London, United Kingdom

Mark Brian Pepys